SELLAS Life Sciences/$SLS
1D1W1MYTD1Y5YMAX
About SELLAS Life Sciences
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- Ticker
- $SLS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- New York, United States
- Website
- sellaslifesciences.com
SLS Metrics
BasicAdvanced
$2.8B
-
-$0.21
2.49
-
Price and volume
Market cap
$2.8B
Beta
2.49
52-week high
$15.88
52-week low
$1.39
Average daily volume
6.8M
Financial strength
Current ratio
18.827
Quick ratio
18.278
Long term debt to equity
0.114
Total debt to equity
0.535
Profitability
Management effectiveness
Return on assets (TTM)
-23.30%
Return on equity (TTM)
-39.63%
Valuation
Price to book
20.67
Price to tangible book (TTM)
20.96
Price to free cash flow (TTM)
-75.795
Free cash flow yield (TTM)
-1.32%
Free cash flow per share (TTM)
-0.186
Growth
Earnings per share change (TTM)
-33.89%
3-year earnings per share growth (CAGR)
-48.44%
SLS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.